As of 2024, the process of obtaining Mounjaro for weight loss or type 2 diabetes management in the UK involves understanding the latest NHS guidelines, private prescription options, eligibility criteria, and current availability.
Eligibility and Availability
To be eligible for Mounjaro (tirzepatide) for weight loss under the NHS, individuals must have a Body Mass Index (BMI) of more than 40 kg/m² and at least three weight-related health problems, such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease.
Alternatively, for those with a BMI ranging from 27 kg/m² to 40 kg/m², eligibility extends if accompanied by conditions like heart attack, stroke, or sleep apnea.
As of October 2024, Mounjaro is poised for phased availability under NHS England. Additionally, due to a shortage of other GLP-1 agonists like Ozempic and Trulicity, Mounjaro began being prescribed in March 2024 for people with type 2 diabetes in England who cannot access their usual medications.
Private Prescription Options
For individuals looking to obtain Mounjaro through private means, it became available for purchase at UK pharmacies or online with a private prescription as of February 2024. Mounjaro was approved for weight loss by the Medicines and Healthcare products Regulatory Agency (MHRA) in November 2023.
When prescribed privately, it is accessible via various online platforms such as AJ Hill Aesthetics, where it is offered with prices starting from £225, depending on the dosage.
How Mounjaro Works
Mounjaro's active ingredient, tirzepatide, mimics the body's GLP-1 and GIP hormones, which regulate energy balance, slow digestion, reduce hunger, and combat cravings. Clinical trials have demonstrated substantial effectiveness, with some patients losing up to 21% of their original weight on the highest dose (15mg).
Usage and Dosage
Mounjaro is administered via a weekly injection. For those starting the treatment, a typical dosing schedule begins with 2.5mg weekly for the first four weeks, incrementally increasing the dose every four weeks until reaching the maintenance dose of 15mg. The injection sites can vary but are usually in the lower stomach, thighs, or back of the upper arms.
Managing Side Effects
Common side effects include nausea, vomiting, diarrhea, and constipation. It's crucial to monitor these and consult with a healthcare provider to manage them effectively. Adjusting eating habits, such as opting for bland foods and increasing fiber intake, can help mitigate some of these side effects. Additionally, regular exercise and adequate hydration are recommended to help manage these side effects.
Considerations and Alternatives
For patients experiencing challenges with other GLP-1 agonists or those unable to access them, Mounjaro offers a viable alternative. It's essential to approach weight loss holistically, incorporating lifestyle changes like a reduced-calorie diet and regular exercise to maximize the benefits of the medication.
To sum up, acquiring Mounjaro in the UK involves navigating NHS eligibility criteria or opting for private prescription channels. With its phased introduction by NHS England amid other GLP-1 agonist shortages, Mounjaro presents a significant addition to diabetes and weight management treatment options.
Comments